At Investor Conferences

Advertisement

Picture Berlin Partner Health Capital Computational Biology 2022 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Asia or involving organisations from these countries.

Total search results: 1140 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
GSK–Spero Therapeutics: tebipenem HBr, 202209– license excl $66m upfront + $375m milestones + royalites ww excl JP + some other Asian countries 2022-09-22
Nuvisan–Gates Foundation: grant, 202209– grant $9.6m for RnD on non-hormonal contraceptive medicines at Nuvisan ICB GmbH 2022-09-20
QLi5 Therapeutics–SEVERAL: investment, 202209 financing round Series A €10m incl SV Investemnt + KHAN + Atinum Investment + DAOL Investment 2022-09-07
Arsenal Biosciences–SEVERAL: investment, 202209 financing round Series B $220m with new + existing investors 2022-09-06
Central Glass–Evotec: investment, 202208–202211 acquisition of Central Glass Germany GmbH for € 1 by Evotec 2022-08-25
eTheRNA–China Grand Pharma: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Grand Pharma 2022-08-23
eTheRNA–SEVERAL: investment, 202208 financing round Series B2 €39m led by existing investor Novalis LifeSciences LLC 2022-08-23
B Medical Systems–Azenta: investment, 202208–202210 acquisition $410m upfront + $50m milestones 100% of B Medical from Navis Capital 2022-08-08
ChemoCentryx–Amgen: investment, 202208– acquisition $3.7b at $52/share ANNOUNCED 2022-08-04
F2G Ltd–Morningside: investment, 202208 financing round totalling $70m inc existing + co-investor Morningside Ventures 2022-08-04
Biosynth Carbosynth–Eucodis Bioscience: industrial enzymes, 202208 collab existent for many years 2022-08-02
Eucodis Bioscience–Biosynth Carbosynth: investment, 202208 acquisition of Eucodis by Biosynth Carbosynth 2022-08-02
Manifold Biotechnologies–Horizon Ventures: investment, 202207 financing round Series A totalling $40m incl new + co-investor Horizon Ventures 2022-07-14
Manifold Biotechnologies–SEVERAL: investment, 202207 financing round Series A $40m led by new investor Triatomic Capital 2022-07-14
Manifold Biotechnologies–Tencent: investment, 202207 financing round Series A totalling $40m incl new + co-investor Tencent 2022-07-14
Manifold Biotechnologies–Triatomic Capital: investment, 202207 financing round Series A totalling $40m incl new + lead investor Triatomic Capital 2022-07-14
Phytolon–SEVERAL: investment, 202207 financing round Series A $14.5m led by DSM Venturing 2022-07-07
BeiGene–InnoRNA: mRNA therapies, 202207– collab strategic r+d ww using InnoRNA LNP-based delivery technology with ww rights for BeiGene 2022-07-06
Astellas–Mogrify: regenerative medicine, 202207– collab research in vivo regenerative medicines for hearing loss 2022-07-05
ReCode Therapeutics–SEVERAL: investment, 202206 financing round Series B extension $120m co-led by Leaps by Bayer + AyurMaya 2022-06-29
F-Star–Sino Biopharm: investment, 202206– acquisition $161m cash tender offer by invoX Pharma at $7.12/share ANNOUNCED 2022-06-23
SPT Labtech–EQT: investment, 202206– acquisition £650m of SPT Labtech by EQT IX Fund from Battery Ventures 2022-06-22
Ariceum Therapeutics–SEVERAL: investment, 202206 financing round Series A €25m co-led by HealthCap + EQT Life Sciences 2022-06-08
Insilico Medicine–SEVERAL: investment, 202206 financing round Series D $60m 2022-06-06
Transition Bio–SEVERAL: investment, 202206 financing round Series A $50m led by Northpond Ventures 2022-06-02
Upstream Bio–Maruho: investment, 202206 financing round Series A totalling $200m incl co-lead investor Maruho Co Ltd 2022-06-02
Upstream Bio–SEVERAL: investment, 202206 financing round Series A $200m co-led by OrbiMed + Maruho Co Ltd 2022-06-02
Watchmaker Genomics–Decheng Capital: investment, 202206 financing round Series A totalling $40m incl lead investor Decheng Capital 2022-06-02
Watchmaker Genomics–Eclipse Ventures: investment, 202206 financing round Series A totalling $40m incl co-investor Eclipse Ventures 2022-06-02
Watchmaker Genomics–SEVERAL: investment, 202206 financing round Series A $40m led by Decheng Capital 2022-06-02
Changjin Biotechnology–SEVERAL: investment, 202206 financing round Series A $20.9m 2022-06-01
Dage Biomedical–SEVERAL: investment, 202206 financing round Series A $22m 2022-06-01
Doma Biopharmaceutical–SEVERAL: investment, 202206 financing round Series A $142.1m 2022-06-01
Helixon–SEVERAL: investment, 202206 financing round Series A $74.7m 2022-06-01
Huisheng Biopharmaceutical–SEVERAL: investment, 202206 financing round Series A $74.8m 2022-06-01
Immuneel Therapeutics–SEVERAL: investment, 202206 financing round Series A $15m 2022-06-01
MegaRobo–SEVERAL: investment, 202206 financing round Series C $300m 2022-06-01
Meta Pharmaceuticals–SEVERAL: investment, 202206 financing round Series A $15m 2022-06-01
Mojia Biotech–SEVERAL: investment, 202206 financing round Series B $80m 2022-06-01
ProfoundBio–SEVERAL: investment, 202206 financing round Series A $70m 2022-06-01
Tessa Therapeutics–SEVERAL: investment, 202206 financing round Series A $126m 2022-06-01
Therorna–SEVERAL: investment, 202206 financing round Series A $42m 2022-06-01
Yueer Gene–SEVERAL: investment, 202206 financing round Series B $50m 2022-06-01
Repertoire Genesis–Eurofins: investment, 202205 acquisition of majority stake by Eurofins Scientific 2022-05-31
Kallyope–Sosei: drug target discovery, 202205– collab to identify + validate gastrointestinal GPCR targets with Sosei Heptares 2022-05-17
Kriya Therapeutics–SEVERAL: investment, 202205 financing round Series C $270m led by Patient Square Capital 2022-05-16
Shionogi–F2G Ltd: olorofim, 202205– strategic collab $100m upfront + $380m milestones + royalties developm + commercialisation in Europe + Asia 2022-05-16
Enzymaster–SEVERAL: investment, 202205 financing round Series C over $45m (CYN300m) led by Yuanbio Venture Capital 2022-05-12
Domain Therapeutics–Panacea Venture: investment, 202205 financing round Series A totalling €39m incl co-lead investor Panacea Venture 2022-05-10
Domain Therapeutics–SEVERAL: investment, 202205 financing round Series A €39m co-led by Panacea Venture + CTI Life Sciences + 3B Future Health Fund 2022-05-10
Domain Therapeutics–Viva Biotech: investment, 202205 financing round Series A totalling €39m incl co-investor Viva BioInnovator 2022-05-10
InxMed–Hyfinity Investments: investment, 202205 financing round Series B expansion $15m from Hyfinity Investments 2022-05-09
Ji Xing Pharmaceuticals–Hovione: ophthalmic, 202205–ww excl license to JX08 programme from Hovione to Jixing 2022-05-09
Ji Xing Pharmaceuticals–RTW Investments: investment, 202205 existent Jixing is backed by RTW Investments LP 2022-05-09
Be Biopharma–SEVERAL: investment, 202204 financing round Series B $130m led by ARCH Venture Partners 2022-04-14
Be Biopharma–Takeda: investment, 202204 financing round Series B totalling $130m incl existing + co-investor Takeda Ventures 2022-04-14
Terumo–Image Box: public relations, 202204 service existent for Terumo Blood and Cell Technologies by Image Box Communications 2022-04-13
Ansa Biotechnologies–Horizons Ventures: investment, 202204 financing round Series A totalling $68m incl existing + co-investor Horizons Ventures 2022-04-11
Ansa Biotechnologies–SEVERAL: investment, 202204 financing round Series A $68m led by Northpond Ventures 2022-04-11
ReViral–Pfizer: investment, 202204– acquisition up to $525m of ReViral by Pfizer 2022-04-07
LimFlow–Balestier: investment, 202204 financing round Series D totalling €36m incl existing investor Balestier family fund 2022-04-06
LimFlow–SEVERAL: investment, 202204 financing round Series D €36m with new + existing investors 2022-04-06
Bio-Medical Science–DNA Script: DNA synthesis system, 202204– distribution of Syntax EDS System by Bio-Medical Science in Korea 2022-04-05
Cold Spring Biotech–DNA Script: DNA synthesis system, 202204– distribution of Syntax EDS System by Cold Spring in China, Taiwan + Hong Kong 2022-04-05
Premas Life Sciences–DNA Script: DNA synthesis system, 202204– distribution of Syntax EDS System by Premas Life Sciences in India 2022-04-05
Research Instruments (SG)–DNA Script: DNA synthesis system, 202204– distribution of Syntax EDS System by Research Instruments in Singapore 2022-04-05
Labster–Andreessen Horowitz: investment, 202204 financing round Series C 2nd tranche totalling $47m incl existing investor Andreessen Horowitz 2022-04-04
Labster–EduCapital: investment, 202204 financing round Series C 2nd tranche totalling $47m incl existing investor EduCapital 2022-04-04
Labster–GGV Capital: investment, 202204 financing round Series C 2nd tranche totalling $47m incl existing investor GGV Capital 2022-04-04
Labster–NPF Technologies: investment, 202204 financing round Series C 2nd tranche totalling $47m incl existing investor NPF Technologies 2022-04-04
Labster–Owl Ventures: investment, 202204 financing round Series C 2nd tranche totalling $47m incl existing investor Owl Ventures 2022-04-04
Labster–Pirate Impact: investment, 202204 financing round Series C 2nd tranche totalling $47m incl new investor Pirate Impact 2022-04-04
Labster–SEVERAL: investment, 202204 financing round Series C 2nd tranche $47m bringing total Series C to $107m 2022-04-04
Labster–Sofina: investment, 202204 financing round Series C 2nd tranche totalling $47m incl new investor Sofina Group 2022-04-04
Asahi Kasei–VectivBio: apraglutide, 202203– excl license $30m upfront + $170m milestones + royalties for developm + marketing in Japan 2022-03-30
Neuron23–SEVERAL: investment, 202203 financing round Series C $100m led by SoftBank Vision Fund 2 2022-03-30
Neuron23–SoftBank: investment, 202203 financing round Series C totalling $100m incl lead investor SoftBank Vision Fund 2 2022-03-30
Qure.ai–HealthQuad: investment, 202203 financing round totalling $40m incl new + co-lead investor HealthQuad 2022-03-29
Qure.ai–MassMutual: investment, 202203 financing round totalling $40m incl existing + co-investor MassMutual Ventures 2022-03-29
Qure.ai–Novo Group: investment, 202203 financing round totalling $40m incl new + co-lead investor Novo Holdings 2022-03-29
Qure.ai–SEVERAL: investment, 202203 financing round $40m co-led by Novo Holdings + HealthQuad + supported by MassMutual Ventures 2022-03-29
InnoRNA–Blue Ocean Capital: investment, 202203 financing round Series B totalling $120m incl co-investor Blue Ocean Capital Group 2022-03-28
InnoRNA–CDH Investments: investment, 202203 financing round Series B totalling $120m incl co-lead investor CDH Investments 2022-03-28
InnoRNA–CPE (CN): investment, 202203 financing round Series B totalling $120m incl existing + co-investor CPE 2022-03-28
InnoRNA–E Fund Capital: investment, 202203 financing round Series B totalling $120m incl co-investor E Fund Capital 2022-03-28
InnoRNA–Fangyuan Capital: investment, 202203 financing round Series B totalling $120m incl existing + co-investor Fangyuan Capital 2022-03-28
InnoRNA–HHF Capital: investment, 202203 financing round Series B totalling $120m incl co-lead investor HHF Capital 2022-03-28
InnoRNA–SEVERAL: investment, 202203 financing round Series B $120m co-led by CDH Investments + HHF Capital 2022-03-28
LifeMine Therapeutics–3W Partners Capital: investment, 202203 financing round Series C totalling $175m incl new + co-investor 3W Partners Capital 2022-03-23
LifeMine Therapeutics–SEVERAL: investment, 202203 financing round Series C $175m led by Fidelity Management and Research 2022-03-23
ITM–ICIF: investment, 202203 financing round totalling €33m incl new investor Indigenous Critical Infrastructure Fund Canada 2022-03-22
ITM–Portland Holdings: investment, 202203 financing round totalling €33m incl exisiting investor PE fund managed by Portland Investment Counsel Inc 2022-03-22
ITM–SEVERAL: investment, 202203 financing round €33m from ICIF + PE fund managed by Portland Investment Counsel Inc 2022-03-22
Nucleai MD–Fosun: investment, 202203 financing round Series B totalling $33m incl existing + co-investor Fosun RZ Capital 2022-03-22
Nucleai MD–SEVERAL: investment, 202203 financing round Series B $33m co-led by Section 32 + Sanofi Ventures 2022-03-22
Nucleai MD–Temasek: investment, 202203 financing round Series B totalling $33m incl existing + co-investor Vertex Ventures 2022-03-22
Ayoxxa–Prosnav Capital: investment, 202203 financing round providing runway for 3-5 years incl new + lead investor Prosnav Capital 2022-03-14
Ayoxxa–SEVERAL: investment, 202203 financing round providing runway for 3-5 years led by new investor Prosnav Capital 2022-03-14
MediLink Therapeutics–Highlight Capital: investment, 202203 financing round Series B totalling $70m incl co-investor Highlight Capital 2022-03-14
MediLink Therapeutics–Legend Capital: investment, 202203 financing round Series B totalling $70m incl co-investor Legend Capital 2022-03-14
1 2 3 4 5 6 7 8 9 10 11 12  next pagenext page



Advertisement

Picture Berlin Partner Health Capital Computational Biology 2022 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture EBD Group ChinaBio Partnering Forum 2022 650x300

» top